Bibliography

Listed below are selected publications from the Myeloma Center at Cornell.

Peer Reviewed Articles

Shi H, Djikeng A, Mark T, Wirtz E, Tschudi C, Ullu E. Genetic interference in Trypanosoma brucei by heritable and inducible double-stranded RNA. RNA. 6(7):1069-76, July 2000.

Niesvizky R, Naib T, Christos P, Jayabalan D, Furst J, Jalbrzikowski J, Zafar F, Mark T, Lent R, Pearse R, Ely S, Leonard J, Mazumdar M, Chen-Kiang S, Coleman M. Lenalidomide-induced myelosuppression is associated with renal dysfunction: Toxicity evaluation of treatment naïve patients undergoing front-line lenalidomide and dexamethasone therapy. Leuk Lymphoma. 2007 Dec;48(12):2330-7.

Mark T, Niesvizky R. The treatment of multiple myeloma and myelodysplastic syndromes with immunomodulatory agents. US Oncol Disease. 2007.Vol 2:26-30.

Niesvizky R, Martínez-Baños D, Jalbrzikowski J, Christos P, Furst J, DeSancho M, Mark T, Pearse R, Mazumdar M, Zafar F, Pekle K, Rambo A. Leonard J, Jayabalan D, Coleman M. Prophylactic low-dose aspirin is effective antithrombotic therapy for combination treatments of thalidomide or lenalidomide in myeloma. Leukemia and Lymphoma. 2007 Dec;48(12):2330-7.

Niesvizky R, Jayabalan D, Christos P, Furst J, Naib T, Ely S, Jalbrzikowski J, Pearse R, Zafar F, Pekle K, Lent R, Mark T, Cho H, Shore T, Tepler J, Harpel J, Schuster M, Mathew S, Leonard J, Mazumdar M, Chen-Kiang S, Coleman M. BiRD (Biaxin®[clarithromycin]/ Revlimid®[lenalidomide]/ dexamethasone) Combination Therapy Results in High Complete and Overall Response Rates in Treatment-Naïve Symptomatic Multiple Myeloma. Blood. 2008 Feb 1;111(3):1101-9.

Mark T, Stern J, Furst JR, Jayabalan D, Zafar F, LaRow A, Pearse RN, Harpel J, Shore T, Schuster MW, Leonard JP, Christos PJ, Coleman M, Niesvizky R. Stem cell mobilization with cyclophosphamide overcomes the suppressive effect of lenalidomide therapy on stem cell collection in multiple myeloma. Biol Blood Marrow Transplant. 2008 Jul;14(7):795-8.

Mark T, Jayabalan D, Pearse R. et al. Atypical Serum Immunofixation Patterns are frequently associated with immunomodulatory therapy and herald complete response in multiple myeloma. British Journal of Hematology. 2008. Dec;143(5):654-60.

Mark T, Niesvizky R, Coleman M. The Novel Agents in Multiple Myeloma: An Exciting Saga. Cancer. 2008. Nov;115(2):236-42.

Mark T, Martin P, Leonard JP, Niesvizky R. Milatuzumab: a promising new agent for the treatment of lymphoid malignancies. Expert Opin Investig Drugs. 2009. Jan;18(1):99-104.

10) Mark T, Coleman M, Niesvizky R. Use of Lenalidomide in Relapsed or Refractory Multiple Myeloma. Asia-Pacific Journal of Oncology & Hematology. 2009;1(2):1-5.

Niesvizky R, Coleman M, Mark T. Best Practices in the Management of Newly Diagnosed Multiple Myeloma Patients Who Will Not Undergo Transplant. Oncology. 2010;24(3):14-21.

Gay F, Rajkumar SV, Jayabalan D, Kumar S, Mark T, Dispenzieri A, Pearse R, Gertz MA, Leonard JP, Lacy MQ, Cheng-Kiang S, Roy V, Coleman M, Lust JA, Witzig TE, Fonseca R, Kyle RA, Greipp PR, Stewart AK, and Niesvizky R. Superiority Of Clarithromycin (Biaxin)-Lenalidomide-low-dose dexamethasone (BiRd) Versus Lenalidomide-low-dose Dexamethasone (Rd) As Initial Therapy for Newly Diagnosed Multiple Myeloma. Am J Hematol. 2010 Sep;85(9):664-9.

Niesvizky R, Ely S, Mark T, Aggarwal S, Gabrilove J, Wright JJ, Chen-Kiang S and Sparano JA. Phase II trial of the histone deacetylase inhibitor romidepsin for the treatment of refractory multiple myeloma. Cancer. 2011 Jan;117(2):336-42. Epub.

Richardson PG, Lacy M, Mark T. Pomalidomide: a new immunomodulatory agent with potent antiproliferative effects and therapeutic promise in the treatment of relapsed and refractory multiple myeloma. Blood Reviews Supplement. In review.

Book Chapters

Mark T, Pearse RN. Pathophysiology of Bone Disease in Multiple Myeloma. Myeloma Therapy: Pursuing the Plasma Cell. Edited by: S. Lonial. Humana Press, Totowa, NJ. December 2008. pp 435-454.

Recent Meeting Abstracts (2009-2011 only)

American Society of Hematology Meeting December 2009

Niesvizky R, Ely S, Jayabalan S, Manco M, Singhal S, Crann M, Courtney R, DuFresne C, Wilner K, Chen I, Mark T, Leonard JP, Coleman M, DiLiberto M, Huang X, Chen-Kiang S. Phase I Trial of PD 0332991, a Novel, Orally-Bioavailable CDK4/6-Specific Inhibitor Administered in Combination with Bortezomib and Dexamethasone to Patients with Relapsed and Refractory Multiple Myeloma.

Mark T, Coleman M, Jayabalan D, Pearse R, Zafar F, Ely S, Manco M, Crann M, Leonard JP, Chen-Kiang S, Niesvizky R. T-Bird (thalidomide, clarithromycin/[Biaxin®], lenalidomide/[Revlimid®], Dexamethasone) Therapy for Upfront Use in Symptomatic Multiple Myeloma.

Gay F, Rajkumar SV, Jayabalan D, Kumar S, Mark T, Dispenzieri A, Pearse R, Gertz MA, Leonard JP, Lacy MQ, Chen-Kiang S, Roy V, Coleman M, Hayman SR, Buadi F, Lust JA, Witzig TE, Fonseca R, Kyle RA, Greipp PR, Stewart AK, Niesvizky R. Clarithromycin(Biaxin)-Lenalidomide-Low-Dose Dexamethasone (BiRd) Versus Lenalidomide-Low-Dose Dexamethasone (Rd) as Initial Therapy for Newly Diagnosed Multiple Myeloma.

Manco M, Mark T, Jayabalan D, Zafar F, Pearse R, Crann M, Leonard JP, Chen-Kiang S, Coleman M, Niesvizky R. Bortezomib in Combination with Dexamethasone and Pegylated Liposomal Doxorubicin (DoVeD) Breaks Plateau Responses Following Initial Induction Therapy in Multiple Myeloma: Results of a Phase II Pilot Study.

American Society of Clinical Oncology Meeting June 2010

Ruan J, Mark T, Allan J, Morrison J, Koirala A, Martin P, Coleman M, Lachs M, Niesvizky R, and Leonard JP. Participation of elderly patients with lymphoma and myeloma in clinical trials of novel agents.

Mark T, Koirala A, Pearse RN, Zafar F, Jayabalan D, Leonard JP, Coleman M, Niesvizky R. An evaluation of the role of bone marrow biopsy in patients with multiple myeloma who achieve an unconfirmed stringent complete remission.

International Society of Hematology Meeting October 2010

Mark T, Koirala A, Pearse R, Pekle K, Zafar F, Coleman M, Niesvizky R. Clarithromycin Deepens Response in Patients with Multiple Myeloma at Plateau With Thalidomide Plus Dexamethasone.

Mark T, Koirala A, Pearse R, Zafar F, Pekle K, Christos P, Coleman M, Niesvizky R. Clarithromycin Increases Dexamethasone Exposure in Multiple Myeloma.

Mark T, Koirala A, Pearse R, Coleman M, Niesvizky R. Clinical Outcomes of Persons With Multiple M-Spikes at Initial Diagnosis in Multiple Myeloma.

American Society of Hematology Meeting December 2010

Mark T, Rossi A, Pearse R, Coleman M, Bernstein D, Zafar F, Gergis U, Shore T, Niesvizky R. A Comparison of Chemotherapy + G-CSF Versus Plerixafor (Mozobil®) + G-CSF for Stem Cell Mobilization In Patients with Multiple Myeloma Treated with Lenalidomide.

Mark T, O'Loughlin J, Coleman M, Jayabalan D, Pearse R, Zafar F, Ely S, Manco M, Mignott P, Leonard J, Chen-Kiang S, Niesvizky. Updated Report of T-Bird (thalidomide, clarithromycin/ [Biaxin®], lenalidomide/[Revlimid®], Dexamethasone) Therapy for Upfront Use In Symptomatic Multiple Myeloma.

American Society of Bone Marrow Transplantation Tandem Meeting February 2011

Ward M, Mark T, Manco M, Stern J, O'Loughlin J, Shore T, Pearse R, Zafar F, Jayabalan D, Skerrett D, Chen-Kiang S, Lane M, Niesvizky R. High-yield of CD34+ cells with bortezomib-based mobilization regimen is associated with specific genomic expression patterns, decrease in SDF-1 plasma levels and up-regulation of CXCR4 in multiple myeloma (MM) patients.

Mark T, Niesvizky R, Gergis U, Pearse R, Mayer S, Feldman E, Shore, R. A Phase 1 Study of Bendamustine and Melphalan Conditioning for Autologous Stem Cell Transplant with Multiple Myeloma.

American Society of Hematology Meeting December 2011

Mark T, Rodriguez M, Shah M, Quinn R, Campbell J, Abdullah R, Pearse R, Zafar F, Pekle K, Mignott P, Jayabalan D, Ely S, Coleman M, Chen-Kiang S, Niesvizky R. ClaPD (Clarithromycin/[Biaxin®], Pomalidomide, Dexamethasone) Therapy in Relapsed or Refractory Multiple Myeloma.

Gergis U, Roboz G, Ritchie E, Scandura J, Carlson K, Shore T, Mayer S, Mark T, Pearse R, Greenberg J, Cucrico T, ippoliti C, McKenna M, Feldman E. A Novel Sequential Treatment Utilizing CPX-351 As Salvage Chemotherapy Followed by a Reduced Intensity Conditioning Allogeneic Stem-Cell Transplantation for Patients with Refractory Leukemia.

Mark T, Shah M, Rodriguez M, Quinn R, Pearse R, Zafar F, Pekle K, Mignott P, Jayabalan D, Ely S, Coleman M, Chen-Kiang S, Nievizky R. T-Bird (thalidomide, clarithromycin/[Biaxin®], lenalidomide/[Revlimid®], Dexamethasone) Therapy in Newly Diagnosed Symptomatic Multiple Myeloma.

Mark T, Reid W, Niesvizky R, Gergis U, Pearse R, Mayer S, Coleman M, Feldman E, Shore T. A Phase 1 Study of Bendamustine and Melphalan Conditioning for Autologous Stem Cell Transplant in Multiple Myeloma.